All In Biotech

Drug Trial Radar · NCT05054751

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Oct 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Sep 10, 2021

Primary completion

Dec 2, 2022

Study completion Mar 30, 2024

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • GB491+ FulvestrantDrug

    GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial. Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.

  • Placebo+FulvestrantDrug

    Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial. Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by the investigatorTime frame: Approximately 1.5 years

Locations

54 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Chaoyang Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

  • Cancer hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital , Capital Medical University

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Chognqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First people's hospital of Foshan

    Foshan, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Guangdong provincial TCM hospital

    Guangzhou, Guangdong, China

  • Meizhou People's Hospital

    Meizhou, Guangdong, China

  • Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center Shenzhen Cancer Hospital

    Shenzhen, Guangdong, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Hainan Third People's Hospital

    Sanya, Hainan, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Affiliated hospital of Hebei University

    Shijiazhuang, Hebei, China

  • Harbin Medcial Univercity cancer hospital

    Haerbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The Affiliated hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Provincial Hospital

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Bethune First Hospital Of Jilin University

    Changchun, Jillin, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Liaoning Cancer hospital & Institute

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Shandong Provincial Qianfoshan Hospital

    Jinan, Shandong, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.